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Collisionally activated decomposition (CAD) of a protonated cyclic peptide produces a
superposition spectrum consisting of fragments produced following random ring opening of
the cyclic peptide to give a set of acylium ions (or isomeric equivalents) of the same m/z.
Assignment of the correct sequence is often difficult owing to lack of selectivity in the ring
opening. A method is presented that utilizes multiple stages of CAD experiments in an
electrospray ion-trap mass spectrometer to sequence cyclic peptides. A primary acylium ion is
selected from the primary product-ion spectrum and subjected to several stages of CAD.
Amino-acid residues are sequentially removed, one at each stage of the CAD, from the
C-terminus, until a b2 ion is reached. Results are presented for seven cyclic peptides, ranging
in sizes from four to eight amino-acid residues. This method of sequencing cyclic peptides
eliminates ambiguities encountered with other MS/MS approaches. The power of the strategy
lies in the capability to execute several stages of CAD upon a precursor ion and its
decomposition products, allowing the cyclic peptide to be sequenced in an unambiguous,
stepwise manner. (J Am Soc Mass Spectrom 1999, 10, 732–746) © 1999 American Society for
Mass Spectrometry
Cyclic peptides comprise a large body of naturalproducts and synthetic compounds. These pep-tides exhibit remarkable diversity and include
antibiotics [1], toxins [2], immunosuppressants [3], ion-
transport regulators [4], inhibitors of protein binding
[5], and enzyme inhibitors [6]. They often possess
unusual pharmacological properties of importance to
biotechnology and medicine.
The determination of the structures of cyclic peptides
by mass spectrometry has witnessed an evolution in
concert with the developments in mass-spectrometry
instrumentation and techniques. In 1982, an unknown
peptide, a cyclic peptide, was sequenced by tandem
mass spectrometry for the first time by Gross and
co-workers [7]. In 1984, the same group [8] utilized
high-energy, collisionally activated decomposition
(CAD) in an effort to develop a general method to
sequence cyclic peptides. It was then recognized that
the determination of the amino-acid sequences of cyclic
peptides by one stage of tandem mass spectrometry
(MS/MS) was compromised by multiple and indiscrim-
inate ring-opening pathways, resulting in a set of acy-
lium ions of the same m/z. These acylium ions (or their
isomeric equivalents) fragment, giving rise to product-
ion spectra that are superpositions of spectra from
fragmentation of the various ring-opened forms [8].
This is illustrated in Scheme 1 for a hypothetical cyclic
peptide consisting of six amino-acid residues A, B, C, D,
E, and F.
If all ring-opened isomers are formed, the product-
ion spectrum would be a superposition of sets of the
product ions shown at the right of the scheme. It would
be relatively straightforward to assign the amino-acid
sequences, realizing that all six primary acylium ions
are actually present in the spectrum. In practice, how-
ever, not all amide bonds are broken, and there can be
significant differences in the fragment-ion abundances.
These differences may reflect the basicities of the amide
nitrogens because an amide bond with a higher proton
affinity may be more readily opened. This is the case
with some proline-containing cyclic peptides when col-
lisionally activated under high energy conditions; they
afford selectivity by undergoing selective ring cleavage
at the proline residue [8].
Eckart et al. [9] generalized the tandem-mass-spec-
trometry approach by separating the sequencing proce-
dure into two different steps. The first step determines
the connectivity between the amino-acid residues but
does not give their orientations. The second step deter-
mines the orientation of the amino acids. The method,
however, has limitations because several cyclic peptides
with multiple dipeptide connectivities produced over-
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lapping dipeptide and tripeptide fragments that are
seen in the tandem mass spectra. These [10] and other
related approaches [11, 12] have proven useful in se-
quencing several cyclic peptides.
The power of the nuclear-Overhauser-effect (NOE)
techniques of NMR for assigning amino-acid sequences
of cyclic peptides challenges mass spectrometrists to
improve their approach. NOEs measured along the
amide bonds of cyclic peptides furnish the structural
detail, including correct assignments of the connectivity
and orientation of the amino-acid residues [13–19].
Milligrams of highly purified material, however, are
required for the NMR determination. Because cyclic
peptides are usually produced by microorganisms, suf-
ficient amounts of material may not be available. There-
fore, there remains a strong need to improve the sensi-
tive mass spectrometric methods.
In comparison with NMR, mass spectrometry has
distinctive advantages of speed and sensitivity. Mass
spectrometry is also suited to the analyses of mixtures.
Because cyclic peptides lack free N-termini, they are not
amenable to Edman degradation. Cyclic peptides gen-
erally contain large amounts of unusual and uncom-
mon amino acids, which are synthesized by the micro-
organisms that produce them [10]. The challenge of
structure determination has compelled many investiga-
tors to explore alternatives, some of which were men-
tioned above [8]. Another example is the work of
Despeyroux et al. [20] who applied chemical reduction
of cysteine-containing peptides in a reductive matrix
prior to ionization by FAB. The amino-acid sequence of
the resulting linear peptide was then determined by
tandem mass spectrometry from the spectrum pro-
duced by the CAD of the [M 1 H]1.
We report here a strategy incorporating multiple
stages of collisionally activated decomposition in an
electrospray-ionization (ESI), ion-trap mass spectrome-
ter to determine amino-acid sequences of cyclic pep-
tides. Multiple stages of consecutive CAD in an ion trap
offer an opportunity to overcome the limitations caused
by overlapping series of fragments in the tandem mass
spectra of protonated cyclic peptides. Multiple stages of
CAD were previously utilized in the determination of
linkage positions in oligosaccharides [21, 22], in the
distinction of isomeric polycyclic aromatic hydrocar-
bons [23], and the structure of complicated surfactants
[24].
Experimental
Materials
Cyclo(Gln–Trp–Phe–Gly–Leu–Met) was purchased
from BACHEM Bioscience, Inc. (King of Prussia, PA),
cyclo(D-Asp–Pro–D-Val–Leu–D-Trp), cyclo(D-Asp–Pro–
D-Ile–Leu–D-Trp), cyclo(D-Glu–Ala–D-alloIle–Leu–D-
Trp), cyclo(D-ser–Pro–D-Val–Leu–D-Trp), cyclo[Leu–
D-Phe–Gly–NMeAla], and cyclo[Tyr–Phe–Gln–Asn–
Asu]–Pro–Arg–Gly–NH2 were purchased from Sigma
Chemical Co. (St. Louis, MO) and were used without
further purification.
Multistage Low Energy CAD of ESI-produced
[M 1 H]1 Ions
Electrospray experiments were carried out with a Finni-
gan LCQ ion-trap mass spectrometer (San Jose, CA)
equipped with an ESI source. The spray needle was at a
potential of 4.41 kV, and a 4800 kPa coaxial flow of
nitrogen was used to stabilize the spray. The counter
electrode was a heated (199 °C) stainless-steel capillary
held at a potential of 10 V. The tube-lens offset was 65
V, and the electron multiplier voltage was 2803 V.
Helium gas was introduced into the ion trap at a
pressure of 1 mtorr (measured on a remote ion gauge)
to improve the trapping efficiency of the sample ions
introduced into the ion trap. The background helium
gas also served as the collision gas during the collisional
Scheme 1
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activation (CA) event. A typical experimental protocol
consisted of infusing a 200–500 fmol/mL solution of a
cyclic peptide solution in 20/80 MeOH/H2O/1% for-
mic acid into the mass spectrometer via a 250-mL
syringe at a flow rate of 2 mL/min.
For experiments involving multiple stages of CAD,
success depended on determining an optimum combi-
nation of the number of scans, isolation width, and
relative collision energy. Of these parameters, the num-
ber of scans and isolation width were most important.
The strategy in multiple CAD experiments was to use
larger isolation widths (2–5 m/z) for the first stages of
CAD to admit sufficient ions into the trap, whereas a
narrow isolation width (;1 m/z) was used at the final
CAD stage. The percentage relative collision energy
was always adjusted such that the relative abundance
of the precursor in the product-ion spectrum was ap-
proximately 10%–30%; generally the range of collision
energy was 0.75–1.4 eV (laboratory frame). Spectra were
acquired in the mass-profile mode, and the number of
scans ranged from 2 to approximately 40, depending on
the relative abundance of the precursor, the number of
stages of CAD, and the nature of the sample.
The peptides were sequenced according to the fol-
lowing procedure. In the first stage, a protonated cyclic
peptide was subjected to CAD to produce the first-
generation, product-ion mass spectrum. In the MS3
step, a given b(n21)JZ ion (b is an acylium ion or
equivalent and n is the number of amino-acid residues
in the peptide as is discussed in the Nomenclature
section at the end of the Experimental) was selected
from the product-ion spectrum and then subjected to
another stage of CAD. The resulting second-generation,
product-ion spectrum (MS3) contained sequence ions
from b(n22)JZ to b2JZ. Next, b(n22)JZ was selected from
the spectrum of the second-generation, product ions
and subjected to another stage of CAD to furnish the
third-generation, product-ion spectrum (MS4), ranging
from b(n23)JZ to b2JZ. This procedure was repeated until
the precursor ion had been reduced to b2JZ, or the
capability for further stages of CAD was exhausted
owing to the loss of precursor-ion signal.
Sample amounts ranged from 1 to 100 pmol, depend-
ing on the number of stages and the size of the peptide.
These quantities do not, however, represent detection
limits, and no efforts were made to determine detection
limit, ability to quantify, and other analytical issues.
High Energy CAD of FAB-produced [M 1 H]1
Ions
High-energy CAD spectra of cyclo(D-Asp–Pro–D-Val–
Leu–D-Trp), cyclo(D-Asp–Pro–D-Ile–Leu–D-Trp), and
cyclo(D-ser–Pro–D-Val–Leu–D-Trp) were acquired on
a VG ZAB-T four-sector instrument (Manchester, UK)
[25]. The matrix, 0.5 mL of 3-nitrobenzyl alcohol (Al-
drich Chemical Co., Milwaukee, WI), was placed on a
FAB probe tip, and 0.5 mL of a 2-nmol/mL peptide
solution in water was placed on the matrix drop. The
sample was bombarded with a 25-keV cesium beam.
The resulting gas-phase [M 1 H]1 was accelerated to 8
keV and selected by MS1, which had been set at 1500
static resolving power (full width at half maximum).
The collision cell was floated at 4 kV (0.5 of the
acceleration potential). Helium gas was introduced into
the collision cell at a pressure sufficient to attenuate the
precursor-ion beam intensity to 50%. The resulting
product-ion spectrum was acquired by scanning MS2,
which was set at 1000 dynamic resolving power. The
calibration of MS2 was accomplished by using CsI
cluster ions that were generated in an intermediate
source (after MS1) as references. Data acquisition and
analyses were carried out with a VG (Manchester, UK)
data system equipped with a DEC Alpha 3000 worksta-
tion, OPUS V 3.1X software, and a VG SIOS I interface.
Nomenclature
The nomenclature system is an extension of the Roep-
storff and Biemann systems [26] and was used to label
fragment ions. An ion is labeled with a four-part
descriptor with the general formula xnJZ, where “x” is
the designation for the ion (lower case “a”, “b”, “c”).
Thus, a b ion is the traditional acylium ion or isomeric
equivalent, which may lose a carbon monoxide to form
an a ion, and n is the number of amino-acid residues in
the ion. J and Z are the one-letter (upper-case) codes for
the two amino-acid residues connecting the backbone
amide or ester bond, J–Z, that was broken to form the
decomposing linear ion. J is the N-terminal amino-acid
residue, and Z is the C-terminal amino-acid residue.
The system requires ions to be uniquely identified as
acylium ions, carbocations, cationized species, N-termi-
nal and C-terminal ions, but does not specify the exact
structures or origins of the ions.
Results and Discussion
Representative Cyclic Peptides
We present the CAD mass spectra of five representative
cyclic peptides to illustrate the general approach in
using multistep tandem mass spectrometry to sequence
these materials.
Cyclo(Phe–Gly–Leu–Met–Gln–Trp). The product-ion
spectrum of ESI-produced [M 1 H]1 of cyclo(Phe–Gly–
Leu–Met–Gln–Trp) (Figure 1) is illustrative of the diffi-
culties in interpreting product-ion spectra of protonated
cyclic peptides. We surmise that only two primary
acylium ions, HTrp–Phe–Gly–Leu–Met–Gln1 and
HPhe–Gly–Leu–Met–Gln–Trp1 are formed because
only series of product ions originating from these
precursors are seen. Three of the four remaining linear
sequences, HGly–Leu–Met–Gln–Trp–Phe1, HLeu–Met–
Gln–Trp–Phe–Gly1, and HMet–Gln–Trp–Phe–Gly–
Leu1, which can be formed by ring opening at other
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amino-acid residues, are not detectable. There is evi-
dence for the fourth sequence, HGln–Trp–Phe–Gly–
Leu–Met1, which may undergo loss of ammonia fol-
lowed by sequential losses of Met (to give the m/z 615
ion) and Leu (to give the m/z 502 ion), underscoring the
complexity endemic in first-generation, product-ion
spectra of cyclic peptides.
The second-generation, product-ion spectrum of
HPhe–Gly–Leu–Met–Gln1, m/z 577 (Figure 1B) shows a
set of sequence ions, down to b2FW. This precursor ion
was chosen to demonstrate the ability of the method to
extract structural data from low-abundance ions. The
amino-acid residues are preferentially lost from the
C-terminus of the ring-opened acylium ion or equiva-
lent, not from the N-terminus. Because we studied a
limited number of cyclic peptides, we cannot yet con-
clude that this is a general phenomenon.
Endothelin A (ETA) selective receptor antagonist cyclo(D-
Asp–Pro–D-Val–Leu–D-Trp). The set of spectra for se-
quencing endothelin A (ETA) selective receptor antago-
nist, cyclo(D-Asp–Pro–D-Val–Leu–D-Trp), cyclic
peptide, is shown in Figure 2. Figure 2A is the first-
generation, product-ion spectrum of the protonated
molecule, showing a superposition of random frag-
ments arising from five possible ring-opened, linear
sequences. Figure 2B,C are the results of consecutive
multistep CAD experiments, showing stepwise frag-
mentation of the acylium ion (or equivalent), HPro–
Val–Leu–Trp1, to furnish sequence to b2PD at m/z 197.
These experiments indicate that cyclo(D-Asp–Pro–D-
Val–Leu–D-Trp) fragments nearly exclusively by step-
wise scission of amino acid residues from the C-termi-
nal side of the peptide, and that no detectable
competing N-terminal fragmentation occurs.
The b2PD ion is stable, and the fourth order (MS
5)
CAD spectrum of the ion (not shown) does not produce
the protonated proline residue (b1PD); instead, an unin-
formative loss of carbon monoxide forms an a2PD at m/z
169. Even MS6, which was designed to look at the a2PD
ion of m/z 169, produced only the immonium ion of
proline at m/z 70 instead of b1: [a2PD m/z 169, MS
6] 3
Figure 1. (A) First-generation, product-ion mass spectrum of protonated cyclo(Phe–Gly–Leu–Met–
Gln). (B) Second-generation (MS3) product-ion spectrum of the b5FW ion HPhe–Gly–Leu–Met–Gln
1,
formed by ring scission at the Phe–Trp amide bond.
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[m/z 70 (100%)]. The inability to detect the b1PD ion is
consistent with the stability of b2 ions [27]. This out-
come does not allow the order of the first two amino
acids (whether Pro–Val or Val–Pro) to be ascertained,
leaving the connectivity of the amino acid residues as:
Pro–Val–Leu–Trp–Asp or Val–Pro–Leu–Trp–Asp. One
approach to resolve this ambiguity is to obtain the CAD
mass spectrum of a reference a2 ion m/z 169, generated
from a standard reference Pro–Val dipeptide. Its prod-
uct-ion mass spectrum is nearly identical to that of the
a2 ion generated from multistep CAD experiments
(MS6) on HPro–Val–Leu–Trp1 (Figure 2A,B,C): [a2 m/z
169, MS3] 3 [m/z 70 (100%)]. As further confirmation,
we obtained the CAD spectrum of a reference a2 ion at
m/z 169, generated from the reference Val–Pro dipep-
tide, and found that the spectrum was different from
that of the a2 ion from the reference Pro–Val dipeptide.
We discuss later in this article another approach to this
problem.
Endothelin A (ETA) selective receptor antagonists cyclo(D-
Asp–Pro–D-Ile–Leu–D-Trp) and cyclo(D-Ser–Pro–D-Val–
Leu–D-Trp). It would be instructive to know how the
fragmentation chemistry behind the foregoing spectra
of cyclo(D-Asp–Pro–D-Val–Leu–D-Trp) would be af-
fected if any amino-acid residue is replaced with a
different one. If the method is general, the results
should be predictable, regardless of the amino-acid
composition of the cyclic peptide. Moreover, if our
hypothesis is correct that low-energy collisional activa-
tion causes predominate fragmentation at the acylium-
ion terminus, then it is important to initiate an experi-
mental test that the observed fragmentation pathways
are not related to the type of amino-acid residues at the
N- and C-terminal ends of the decomposing ring-
opened cyclic peptides. We repeated the high order
MS/MS experiments by using two cyclic peptides in
which the Val and Asp residues were substituted with
Ile and Ser, respectively. When Val was replaced with
Ile, the peptide has the structure cyclo(D-Asp–Pro–D-
Ile–Leu–D-Trp), and the cyclic peptide is a powerful
ETA selective receptor antagonist. Its product-ion mass
spectra are shown in Figure 3A,B,C, and for the cyclic
peptide in which Asp is replaced with Ser, cyclo(D-Ser–
Pro–D-Val–Leu–D-Trp), the product-ion spectra are
shown in Figure 4A,B,C,D.
The product-ion mass spectrum of protonated cy-
clo(D-Asp–Pro–D-Ile–Leu–D-Trp) (Figure 3A) is a su-
perposition spectrum consisting of fragments arising
from random ring-opening pathways. One ring-open-
ing pathway, the scission of the Asp–Pro amide bond to
form HPro–Ile–Leu–Trp–Asp1, was interrogated in
consecutive, multistep CAD experiments. The third-
generation, product-ion spectrum (Figure 3) shows the
amino-acid sequence down to b2PD at m/z 211. The
spectrum is dominated, however, by the m/z 466 ion
formed by loss of the elements of C3H8. In the MS
4
experiment, the b3PD ion at m/z 324 was selected and
collisionally activated to yield a highly abundant b2PD
ion at m/z 211 (Figure 3C). Collisional activation of the
b2PD ion in an MS
5 step produced only the a2PD ion at
m/z 183. In the MS6 step, with a2PD ion as the precursor,
only the immonium ions of Pro and Ile were produced:
m/z 70 (100%) and 86 (20%), respectively.
To determine the orientation of the N-terminal
dipeptide (whether Pro-Ile or Ile-Pro), we obtained the
CAD mass spectrum of a reference a2 ion of m/z 183
from a reference Pro-Ile dipeptide. The spectrum is
nearly identical to that of the a2PD ion (of m/z 183)
obtained from the multistep CAD (MS6) experiments,
starting with HPro–Ile–Leu–Trp1 of Figure 3A,B,C. In
contrast, the CAD spectrum of an ion with the retro
sequence generated from the dipeptide Ile–Pro is dif-
ferent from that of Pro–Ile: a2 (m/z 183, MS
4)3 [m/z 155
(100%), m/z 138 (0.6%), m/z 127 (0.9%), m/z 115 (0.6%),
m/z 88 (0.5%), m/z 86 (0.5%), m/z 70 (1%)].
A similar set of multistep CAD experiments (up to
MS6 ending with the a2PS ion at m/z 169) was carried out
on cyclo(D-Ser–Pro–D-Val–Leu–D-Trp) (Figure 4A,B,
C), using the primary acylium ion or equivalent HPro–
D-Val–Leu–D-Trp–D-Ser1 (as will be established from
the MSn experiments). The type of fragmentation ob-
served is identical to that of cyclo(D-Asp–Pro–D-Ile–
Leu–D-Trp) of Figure 3. The experiments demonstrate
that the fundamental fragmentation chemistry is the
same for all three cyclic peptides: amino acid residues
are sequentially removed from the C-terminus. In con-
trast to the high-energy CAD of proline-containing
cyclic peptides [8], no preferential ring opening oc-
curred at the proline residue.
These experiments on closely related peptides also
enabled us to rationalize the identity and origin of the
abundant ion at m/z 452 in Figure 2B. This ion is formed
by the loss of the elements of C3H8 from the precursor
ion of m/z 496. There are two possible sources of C3H8.
One is loss of the entire valine side chain accompanied
by H transfer to form an ion that is similar to a v ion
[28–31] except it is missing the C-terminal OH. The
product ion should be especially stable because it
contains an a,b-unsaturated carbonyl moiety. The ele-
ments of C3H8 can also be eliminated from the side
chain of Leu to form a d3PD ion [28–31] but by a
mechanism that is different than that pertaining to
high-energy collisional activation. When Val was re-
placed with Ile (Ile cannot lose C3H8), the loss of C3H8
still occurs to give the ion of m/z 466 (Figure 3B). This is
evidence that this loss is from the side chain of Leu and
not that of Val.
High energy CAD of FAB-produced [M 1 H]1 ions. We
examined the high-energy CAD of the [M 1 H]1 of
proline-containing cyclic peptides cyclo(D-Asp–Pro–D-
Val–Leu–D-Trp) (Figure 5A), cyclo(D-Asp–Pro–D-Ile–
Leu–D-Trp) (Figure 5B), and cyclo(D-ser–Pro–D-Val–
Leu–D-Trp) (Figure 5C). This was done to achieve a
reference point demonstrating that the set of cyclic
peptides chosen for our study does not have special
properties but rather behaves in the expected way by
736 NGOKA AND GROSS J Am Soc Mass Spectrom 1999, 10, 732–746
high-energy CAD. Indeed, high-energy collisional acti-
vation causes extensive fragmentation, underscoring
the need for an alternative approach for sequencing
cyclic peptides. The product-ion spectra show forma-
tion of highly abundant, low-mass fragments and low-
abundance, high-mass ions. Indiscriminate ring open-
ing, even for cyclic peptides containing proline [8],
occurs. Ring opening at Pro is not dominant contrary to
the high-energy collisional activation of proline-con-
taining cyclic peptides that were previously studied [7,
8]. Thus, this set of cyclic peptides is an appropriate test
of the capability of multistep, low-energy CAD.
Cyclic Peptides Containing Two or More Adjacent
Amino-Acid Residues That Are Identical
Multiple stages of CAD are especially effective in re-
solving isobaric ions that occur in tandem mass spectra
when the precursor ion contains several adjacent ami-
no-acid residues that are identical or isomeric. For
example, the ion at m/z 500 (loss of 113 Da from the
protonated molecule) in the CAD mass spectrum of
cyclo(D-Glu–Ala–D-alloIle–Leu–D-Trp) (Figure 6) is
likely to be a mixture of two isobaric ions formed by the
loss of either Ile or Leu to give identical m/z product
Figure 2. Multistep CAD mass spectra of cyclo(Asp–Pro–Val–Leu–Trp). (A) First-generation, prod-
uct-ion mass spectrum of the protonated molecule. (B) Second-generation (MS3), product-ion
spectrum of the b4PD ion HPro–Val–Leu–Trp
1 formed by ring scission at the Pro–Asp amide bond. (C)
Third-generation (MS4) product-ion spectrum of the b3PD ion, HPro–Val–Leu
1
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ions. When the m/z 500 ion was selected as a precursor
in an MS3 experiment, two sets of amino-acid sequence
ions, arising from the fragmentation of the linear acy-
lium ions (or isomeric equivalents) HLeu–Trp–Glu–
Ala1 and HTrp–Glu–Ala–Ile1, were obtained (Figure
6B). The two fragmentation pathways can be easily
resolved in a consecutive stage of MS/MS, and the
cyclic peptide can be sequenced without ambiguity.
Complete Connectivity of Amino-Acid Residues
Can be Obtained by Sequencing Two Ring-Opened
Forms of the Protonated Molecule
The CAD mass spectra of cyclo(D-Ser–Pro–D-Val–Leu–
D-Trp) (Figure 4) show that the final stage of connec-
tivity cannot be established by following one series of
fragments because the b2PS ion cannot fragment further
Figure 3. Multistep CAD spectra of cyclo(Asp–Pro–Ile–Leu–Trp). (A) First-generation, product-ion
spectrum of the protonated molecule. (B) Second-generation (MS3), product-ion spectrum of the b4PD
ion HPro–Ile–Leu–Trp1 formed by ring scission at the Pro–Asp amide bond. (C) Third-generation
(MS4), product-ion spectrum of the b3PD ion, HPro–Ile–Leu
1
738 NGOKA AND GROSS J Am Soc Mass Spectrom 1999, 10, 732–746
to produce b1PS. One approach to determining full
connectivity is to obtain for comparison the CAD spec-
tra of reference ions, as for the CAD spectra shown in
Figures 2 and 3. Another approach for resolving the
problem is to sequence at least two isomeric, ring-
opened [M 1 H]1 ions, as illustrated by a study of
cyclo(D-Glu–Ala–D-allo-Ile–Leu–D-Trp) (Figure 6).
Figure 6A is the first-generation, product-ion spec-
trum, showing a superposition of fragment ions arising
from indiscriminate ring-opening pathways. Figure 6B
is the product-ion spectrum of both HTrp–Glu–Ala–Ile1
(m/z 500) and HLeu–Trp–Glu–Ala1 (m/z 500). By select-
ing the m/z 387 ion for additional MS/MS, we are able
to sequence the former acylium ion and see sequential
losses down to b2WL ion at m/z 316. To sequence the
latter ion, HLeu–Trp–Glu–Ala1, we chose the m/z 429
Figure 4. Multistep CAD mass spectra of cyclo(Ser–Pro–Val–Leu–Trp). (A) First-generation, prod-
uct-ion mass spectrum of the protonated molecule. (B) Second-generation (MS3), product-ion
spectrum of the b4PS ion HPro–Val–Leu–Trp
1 formed by ring scission at the Pro–Ser amide bond. (C)
Third-generation (MS4), product-ion spectrum of the b3PD ion HPro–Val–Leu
1. (D) Fourth-generation
(MS5), product-ion spectrum of the b2PS ion, HPro–Val
1.
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ion, and it manifests the expected fragmentation pro-
cesses down to the b2LI at m/z 300 (spectra not shown).
The question that remains is the sequence of the last
two residues: is it Leu–Trp or Trp–Leu? The complete
connectivity can be established by sequencing another
ring-opened form; for example, the m/z 427 ion (formed
by loss of Trp from HGlu–Ala–Ile–Leu–Trp1), which
can be selected from the first-generation, product-ion
spectrum of Figure 6A. A major fragmentation of the
m/z 427 ion is loss of Leu, establishing that the sequence
is Leu–Trp. This connectivity could never be established
with any confidence by interpreting the product-ion
spectrum of the parent [M 1 H]1, given the low rela-
tive abundances of the relevant ions in Figure 6A. The
multistep spectra reveal the following processes: b4EW
(m/z 427, MS3)3 [m/z 409 (52%), m/z 399 (100%), m/z 381
(20%), m/z 342 (19%), b3EW, m/z 314 (70%), m/z 292 (40%),
m/z 268 (5%), m/z 243 (6%), m/z 227 (20%), b2EW, m/z 201
Figure 5. High-energy CAD spectra of the [M 1 H]1 of proline-containing cyclic peptides cyclo(D-
Asp–Pro–D-Val–Leu–D-Trp) (A), cyclo(D-Asp–Pro–D-Ile–Leu–D-Trp) (B), and cyclo(D-ser–Pro–D-
Val–Leu–D-Trp) (C). The notable ammonium ions for Pro and Leu are missing in (A) and (C) because
the scans were terminated at m/z values that are greater than m/z 86.
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(4%), m/z 183 (5%)]; b3EW (m/z 314, MS
4) 3 [m/z 299
(16%), m/z 296 (70%), m/z 286 (30%), m/z 268 (25%), m/z
243 (40%), b2EW, m/z 201 (100%)]; [b2EW m/z 201, MS
5]3
[m/z 183 (100%), a2EW, m/z 173 (16%)]; a2EW (m/z 173,
MS6)3 [m/z 155 (100%), m/z 101 (45%)]. The facile water
losses probably originate at the terminal Glu residue.
Cyclic Peptides Containing Linear Peptide
Branches
Collisional activation of a cyclic peptide bearing a linear
peptide moiety does not afford cleavage of the cyclic
peptide backbone, even when a sodium adduct is
Figure 6. Multistep CAD mass spectra of cyclo(D-Glu–Ala–D-alloIle–Leu–D-Trp). (A) First-genera-
tion, product-ion spectrum of the protonated molecule. (B) Second-generation (MS3), product-ion
spectrum of the b4WL and b4LI ions, HLeu–Trp–Glu–Ala
1 and HTrp–Glu–Ala–Ile1, respectively. (C)
Third-generation (MS4), product-ion spectrum of the b3WL ion, HTrp–Glu–Ala
1. (D) Fourth-genera-
tion (MS5), product-ion mass spectrum of the b2WL ion, HTrp–Glu
1.
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subjected to high-energy, CAD [12]. Thus, a great deal
of structural information, including the amino acid
sequence of the cyclic peptide moiety, remains inacces-
sible. The multistage tandem-MS strategy provides a
solution to this shortcoming. Applying multiple stages
of CAD, we can separate and sequence independently
both the linear-peptide and the cyclic-backbone moi-
eties, as was reported earlier [26].
A vasopressin fragment, [Asu1,6, Arg8]-vasopressin,
cyclo[Tyr–Phe–Gln–Asn–Asu]–Pro–Arg–Gly–NH2, is
used to illustrate the approach. The peptide consists of
eight amino-acid residues, five in the backbone and
three in the linear chain. The product-ion spectrum of
the [M 1 H]1 ion (Figure 7) consists of three distinct
regions. The molecular-ion region shows that the [M 1
H]1 at m/z 1033 loses small, neutral fragments (NH3,
H2O, CO, H2NCOCH2NH2, and H2NCOCH2NH2 and
CO). A second region contains information on the cyclic
peptide moiety and shows that the small neutral frag-
ments (NH3, H2O, CO, HCONH2, HCONH2, and NH3)
are again lost in its fragmentation. The third region of
the spectrum contains information on the protonated
linear peptide moiety at m/z 328. It is desirable that all
components of the molecule are present in the spectrum
because each can be selected independently and se-
quenced.
The gas-phase chemistry leading to the formation of
the ions is highly dependent on the site of initial
protonation to form the [M 1 H]1. If protonation oc-
curs initially on the proline residue, the linear peptide
moiety should be ejected as a neutral species HPro–
Arg–Gly–NH2, and the cyclic peptide moiety, cyclo-
(Gln–Asn–Asu1–Tyr–Phe), is formed as seen in the
spectrum by the peak corresponding to the acylium ion
or its equivalent at m/z 706 (we depict protonation to
occur at the nitrogen as a matter of convenience, real-
izing that the more favored site of protonation is the
carbonyl group). On the other hand, when protonation
occurs on the linear peptide chain, the linear peptide
moiety is produced as seen by the peak for [HPro–Arg–
Gly–NH2 1 H]
1 at m/z 328. In this scenario, the proline
residue is protonated by the amide hydrogen of Asu via
an intramolecular proton transfer, resulting in the cy-
clization of the Asu residue to form a bicyclic neutral
ketone. The peptide backbone is not observed in the
spectrum because it is lost as a neutral species. Both
reactions are illustrated in Scheme 2.
Why don’t the relative abundances of the side chain
at m/z 328 and the backbone at m/z 706 correlate with
the known basicities of arginine and proline, respec-
tively [32–34]? The answer may be that the displace-
Figure 7. Multistep CAD spectra of cyclo[Tyr–Phe–Gln–Asn–Asu]–Pro–Arg–Gly–NH2. (A) First-
generation, product-ion spectrum of the protonated molecule. (B) Second-generation (MS3), product-
ion spectrum of the cyclic-peptide moiety at m/z 706.
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ment of the linear peptide is limited by the rate of
intramolecular protonation of proline nitrogen.
The cyclic peptide moiety at m/z 706 was collisionally
activated in an MS3 experiment to produce the second-
generation, product-ion spectrum shown in Figure 7B.
The product acylium ion (or isomeric equivalent) HAs-
n–Asu–Tyr–Phe–Gln1 was then selected and sequenced
down to b2NQ (Figure 8A,B,C). In this way, interpreting
the complexity of the spectrum in Figure 7B is avoided
and establishing the sequence is relatively straightfor-
ward by multistep MS/MS. The fragment representing
the linear tripeptide moiety, HPro–Arg–Gly–NH2 1
H]1 at m/z 328, was selected after one stage of colli-
sional activation and sequenced separately. In an MS3
experiment, loss of the C-terminal glycine residue to
produce the dipeptide b2 ion HPro–Arg
1 at m/z 254 was
the dominant reaction path. Further collisional activa-
tion in an MS4 experiment did not produce a b1 ion (the
protonated proline residue). Instead, the b2 ion loses
(NH2)2C¢NH from the arginine side chain.
Scheme 2
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Cyclic Peptides Containing Modified Amino Acid
Residues
The last example is tentoxin [cyclo(Gly–NMeAla–Leu–
dehydro NMePhe)], a representative cyclic peptide con-
taining modified amino acid residues (the CAD mass
spectra are not shown). Tentoxin presents a unique case
for two reasons. First, tentoxin has proven particularly
difficult to sequence correctly by mass spectrometry
because it has three amino acids: Gly, NMeAla, and
Leu, that differ by 28 mass units. As a result, there are
three sets of isomeric dipeptide moieties and some a
ions that have the same nominal mass (Table 1). The
Figure 8. Multistep CAD mass spectra of cyclic-peptide moiety cyclo[Tyr–Phe–Gln–Asn–Asu1]. (A)
Third-generation (MS4), product-ion spectrum of the b4NQ ion HAsn–Asu–Tyr–Phe
1 formed by ring
cleavage at the Asn–Gln amide bond. (C) Fourth-generation (MS5), product-ion mass spectrum of the
b3NQ ion, HAsn–Asu–Tyr
1. (D) Fifth-generation (MS6), product-ion spectrum of the a3NQ ion formed
by decarbonylation of the b3NQ, HAsn–Asu–Tyr
1.
Table 1. Possible isobaric fragment ions (assuming unknown
connectivity and orientation) in a CAD mass spectrum of
protonated tentoxin
Amino acid residue bn(m/z) an(m/z)
Gly 58 30
NMeAla 86 58
Leu 114 86
Gly–NMeAla or
NMeAla–Gly
143 115
NMeLeu–Leu or
Leu–NMeAla
199 171
Gly–Leu or Leu–Gly 171 143
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difference between the a and b ions can be resolved by
exact-mass measurements [35]. The multistep CAD
strategy obviates these difficulties, including the re-
quirement for exact-mass measurements, and tentoxin
can be sequenced in a straightforward manner.
The second point about tentoxin is that we obtained
sequence information for this molecule down to a b1
ion. In the preceding examples, b2 ions did not fragment
further to furnish b1 ions upon collisional activation.
Tentoxin is an exception; it fragments smoothly to an a1
ion. [In the nomenclature for labeling fragment ions, the
modified amino-acid residues in tentoxin are coded as:
dehydro-N-Me-phenylalanine (F9); N-Me-alanine (A9)].
The product-ion mass spectrum of protonated tentoxin
is a summation spectrum, consisting of random frag-
ments arising from ring opening at the Leu–N-MeAla,
N-MeAla–Gly, and (dehydro)N-MePhe–Leu amide
bonds. The ring-opened form of H(dehydro)N-MePhe–
Gly–N-MeAla–Leu1 that results from ring scission at
the (dehydro)N-MePhe–Leu amide bond fragments to
give the b3FL ion H(dehydro)N-MePhe–Gly–N-MeAla
1.
The b3FL ion was selected from this spectrum and
sequenced down to the a1FL ion at m/z 132 in six steps of
consecutive CAD: b3FL (m/z 415, MS
3) 3 [a3FL m/z 274
(24%), b2FL m/z 217 (100%)]; b2FL (m/z 217, MS
4)3 [a2FL
m/z 189 (100%)]; a2FL (m/z 189, MS
5) 3 [b1FL m/z 160
(20%), m/z 146 (100%), a1FL m/z 132 (80%), m/z 120 (10%),
m/z 111 (30%)]; b1FL (m/z 160, MS
6) 3 [a1FL m/z 132
(100%)].
Competing Side Reactions
The CAD mass spectra of HPro-Val-Leu-Trp1 (Figures
2B and 4B) and HPro-Ile-Leu-Trp1 (Figure 3B) contain
fragment ions arising from intramolecular rearrange-
ments. For both product ions, the C-terminal Trp may
cyclize to the N-terminal Pro to form rearranged acy-
lium ions: HLeu-Trp-Pro-Val1 and HLeu-Trp-Pro-Ile1.
Both rearranged ions produce sequence ions of m/z 397
and 300 by losing Val and Pro and Ile and Pro, respec-
tively. Of all the cyclic peptides studied thus far, only
these two acylium ions undergo this rearrangement.
This may be related to the presence of Trp residues at
the C-termini. Furthermore, only these two ions un-
dergo losses of C3H8 from the Leu side chain. It is not
clear whether these two reactions are related.
Conclusions
Protonated cyclic peptides generated by ESI can be
sequenced stepwise in an ion-trap mass spectrometer
by taking advantage of the MSn capabilities. The pro-
cedure involves selecting one of the primary acylium
ions in the first generation of product ions and subject-
ing it to several stages of consecutive CAD. Amino-acid
residues are sequentially deleted from the C-terminus,
principally one at each stage of the CAD experiment,
until b2JZ is reached or the precursor-ion signal is too
weak for another stage of CAD. In most cases, CAD of
b2JZ did not produce b1JZ, requiring that other ap-
proaches be used to obtain the sequence of the two
N-terminal amino-acid residues. One solution is to
sequence at least two primary acylium ions to establish
the complete connectivity of the amino acid residues.
Another approach is to select another primary ion and
sequence it by the multistep method.
This multistep method usually does not suffer from
the mass-range limitations of the ion trap because one
or two residues are removed at each step. The use of
multistep fragmentations also gradually lowers the
low-mass limit so that low-m/z product ions can ulti-
mately be observed.
The method is fast and efficient, and obviates the
need for chemical derivatization or other cumbersome
expedients that consume large amounts of scarce sam-
ples. The method also eliminates the need to interpret
complicated product-ion spectra such as those pro-
duced by high-energy CAD, and requires sample
amounts in the picomol range, depending on the num-
ber of stages, and the size of the peptide.
For an unknown cyclic peptide, one would examine
the product-ion spectrum of the protonated molecular
ion for losses of common amino-acid residues. The
product ions formed by such losses would then be
submitted to higher stages of MS/MS, and the criteria
for selecting the appropriate product ion repeated for
each successive stage. For all cyclic peptides and espe-
cially for cyclic peptides containing unusual amino or
hydroxy acids, a preliminary analysis of amino-acid (or
hydroxy-acid) composition would be helpful.
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